Table 2 VITT diagnosis, location of thrombosis, antithrombotic and IVIG therapy
From: Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT
Patient | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
Cerebral venous sinus thrombosis | Yes | Yes | No | No | Yes | No |
Multiple thromboses | Yes | No | Yes | Yes | Yes | Yes |
Arterial thrombosis | Yes | No | Yes | No | No | No |
Anti-PF4 Ab ELISA positivity –Days after admission | 1 | 5 | 1 | 0 | 1 | N/A |
Initial (1–2 doses) antithrombotic treatment | enoxaparin, aspirin | tinzaparin | enoxaparin, aspirin, ticagrelol | danaparoid | danaparoid | enoxaparin |
IVIG | Yes | Yes | Yes | No | Yes | Yes |
Duration of hospital stay (days) | 2 | 15 | 18 | 7 | 7 | 20 |
Outcome | Fatal | Recovery | Recovery | Recovery | Recovery | Recovery |